TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (DEBIRITUX)
A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours
Sponsor: Biocompatibles UK Ltd
Terminated
Terminated due to poor subject enrolment
Other terminated trials from Biocompatibles UK Ltd
- Liver Cancer · Dec 2018
- Hepatocellular Carcinoma · Phase PHASE3 · May 2017
- Unresectable Metastatic Colo-rectal Cancer · Phase PHASE1/PHASE2 · Mar 2011
More terminations from Biocompatibles UK Ltd
Other Colorectal Cancer trials with similar outcome
A PHASE2 clinical study on Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Biocompatibles UK Ltd and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biocompatibles UK Ltd
- Hans-Joachim Schmoll, MD
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Berka, Germany , Dresden, Germany , Essen, Germany , Esslingen am Neckar, Germany , Frankfurt/M., Germany , Halle, Germany , Hamburg, Germany , Heilbronn, Germany , Magdeburg, Germany , Regensburg, Germany and 2 more locations